G-CSF ATTENUATES VENTRICULAR REMODELLING AFTER ACUTE STEMI. RESULTS OF STem cells Mobilization in Acute Myocardial Infarction
|
|
- Vernon Martin
- 6 years ago
- Views:
Transcription
1 ESC CONGRESS 2010 Stockholm 28 August-1 September G-CSF ATTENUATES VENTRICULAR REMODELLING AFTER ACUTE STEMI. RESULTS OF STem cells Mobilization in Acute Myocardial Infarction C. Malafronte MD Alessandro Manzoni Hospital Lecco, Italy for the STEM-AMI Investigators C. Malafronte MD, L. Lenatti MD, G. Pompilio, F. Gentile MD, L. Squadroni MD, A. Di Lelio MD, M. Pesce PhD, P. Camisasca MD, L. Mircoli MD F. Achilli MD.
2 STEM-AMI TRIAL: rationale G-CSF prevents cardiac remodeling after myocardial infarction by activating the Jak-Stat pathway in cardiomyocytes Harada et al., Nature Medicine 2005;11:305-11
3 STEM-AMI TRIAL: rationale H.Ince, Preservation From Left Ventricular Remodeling by Front-Integrated Revascularization and Stem Cell Liberation in Evolving Acute Myocardial Infarction by Use of Granulocyte-Colony Stimulating Factor (FIRSTLINE-AMI). Circ.2005 M.Valgimigli, Use of granulocyte-colony stimulating factor during acute myocardial infarction to enhance bone marrow stem cell mobilization in humans: clinical and angiographic safety profile. Eur Heart J 2005 S.G. Ellis, Granulocyte colony stimulating factor in patients with large acute myocardial infarction : results of a pilot dose-escalation randomized trial. AHJ 2006 Engelmann MG, Autologous bone marrow stem cell mobilization induced by granulocyte colony stimulating factor after subacute ST segment elevation myocardial infarction undergoing late revascularization. JACC 2006 Rasmus Sejersten Ripa, Stem Cell Mobilization Induced by Subcutaneous Granulocyte-Colony Stimulating Factor to Improve Cardiac Regeneration After Acute ST-Elevation Myocardial Infarction Result of the Double-Blind, Randomized, Placebo- Controlled Stem Cells in Myocardial Infarction (STEMMI) Trial. Circ 2006
4 STEM-AMI TRIAL: rationale 385 patients/8 randomized studies Am Heart J 2008;156: e9
5 STEM-AMI TRIAL: rationale
6 STem cells Mobilization in Acute Myocardial Infarction: STEM-AMI Trial F. Achilli MD a, C. Malafronte MD a, L. Lenatti MD a, F. Gentile MD b, V. Dadone MD b, G. Gibelli MD c, S. Maggiolini MD d, L. Squadroni MD e, C. Di Leo MD f, Burba PhD g, M. Pesce PhD g, L. Mircoli MD a, M.C. Capogrossi MD h, A. Di Lelio MD i, P. Camisasca MD j, Morabito k, G Colombo MD PhD l, and G. Pompilio MD PhD m. a Cardiology Department, A. Manzoni Hospital, Lecco, Italy; b Cardiology Department, Bassini Hospital, Cinisello Balsamo, Milan, Italy; c Cardiology Unit, Clinica San Carlo, Paderno D Adda, Italy; d Cardiology Department, San L.Mandic Hospital, Merate, Lecco, Italy; e Cardiology Department, San Carlo Hospital, Milan, Italy; f Nuclear Medicine Department, A. Manzoni Hospital, Lecco, Italy; g Laboratory of Vascular Biology and Regenerative Medicine, Centro Cardiologico Monzino IRCCS, Milan, Italy; h Laboratory of Vascular Pathology, Istituto Dermopatico dell Immacolata IRCCS, Rome, Italy; I Radiology Department, San Gerardo Hospital, Monza, Italy; j Cardiology Department, San Gerardo Hospital, Monza, Italy; Medical Statistics, k University of Milano; l Laboratory of Immunology and Functional Genomics, Centro Cardiologico Monzino IRCCS, Milan, Italy; m Cardiovascular Surgery Department, Centro Cardiologico Monzino - IRCCS, Milan, Italy European Heart Failure Journal 2010 (in press) San Carlo Hospital Bassini Hospital San Gerardo Hospital Centro Cardiologico Monzino
7 STEM-AMI TRIAL Multicenter, randomised, single blind, placebo controlled 60 Patients randomization ratio 1:1 G-CSF vs. PLACEBO G-CSF s.c. 10 mcg/die for 5 days (1-5 day) vs placebo TIMING Approved by the local Ethics Committee of A. Manzoni Hospital in Lecco (November 9th, 2005) Patients were enrolled in 4 Italian centres between July 2006 and May 2009 Follow-up was completed in November 2009
8 STEM-AMI TRIAL: end points Primary end point was a change of 5% of LVEF, from baseline to 6-months evaluated by MRI. Co-primary end point was a difference of 20 ml of LVEDV by MRI. Secondary end-points were infarct size reduction evaluated by MRI and improvement of myocardial perfusion by SPECT at 6- months. Major cardiac adverse events (MACE) and rate of restenosis were analysed during in-hospital and 6 months follow up. MACE were defined as death, reinfarction, acute heart failure, urgent revascularization and stroke.
9 STEM-AMI TRIAL: Inclusion and exclusion criteria INCLUSION CRITERIA Signed Informed consent Acute anterior STEMI undergoing PCI Time symptom-to-ballon > 2 h and < 12 h Ejection fraction post PCI 45% TIMI flow post PCI 2-3 EXCLUSION CRITERIA Previous myocardial infarction Leukemia, myeloproliferative or myelodysplastic disorders Immune system disease Malignant disease Age > 75 years Life expectancy < 6 months Previous cardiac surgery or stenting within 12 months Coronary lesions needing CAB Platelet count < mm 3 STEMI=ST-elevation myocardial infarction; PCI= percutaneous coronary intervention; CAB=coronary artery bypass; TIMI= thrombolysis in myocardial infarction
10 STEM-AMI TRIAL: FLOW CHART 60 Patients with anterior AMI and FE 45% plus successful PCI/stent Randomization 30 Patients Standard post-ami care Plus PLACEBO 30 Patients Standard post-ami care plus 5 µg/kg bid of G-CSF within 12 h after PCI Echo (day 5) SPECT (day 5) ECG-Holter (day 1-7) Cardiac MRI (day 6) In-hospital f.u. ECG Blood sample Day 30 Echo ECG-Holter Day 90 Echo ECG Holter SPECT Cardiac MRI Coronary angiography Day 180
11 STEM-AMI TRIAL: Demographic and clinical characteristics of study population VARIABLE G-CSF (n 29) Placebo (n 27) p Age, y 61 ± 8 61 ± Male sex, n (%) 29 (100) 24 (89) 0.21 Hypertension, n (%) 14 (48) 18 (67) 0.26 Diabetes, n (%) 6 (21) 3 (11) 0.47 Dyslipidemia, n (%) 17 (59) 16 (59) 0.82 Smoking, n (%) 17 (59) 13 (48) 0.60 Family history of CAD, n (%) 12 (41) 9 (33) 0.73
12 STEM-AMI TRIAL: Biochemical characteristics of study population Blood analysis G-CSF (n 29) Placebo (n 27) p CRP (mg/dl) 1.4 ± ± Pro-BNP (pg/ml) 2094 ± ± WBCs count (x10 3 /mm 3 ) 13 ± 5 12 ± Platelets count (x10 3 /mm 3 ) 196 ± ± Creatinine (mg/dl) 0.87 ± ±
13 STEM-AMI TRIAL: Medication of study population Medication at discharge % G-CSF (n 29) Placebo (n 27) p Aspirin Clopidogrel Statin ACE inhibitors Beta-blockers Diuretics Medication at 6 months of f.u. Statin, % Atorvastatin median dose, mg 35.0 ± ± ACE inhibitors, % Ramipril median dose, mg 6.6 ± ± Betablockers, % Carvedilol median dose, mg 25.4 ± ± Diuretics, % Furosemide median dose, mg 31.2 ± ±
14 STEM-AMI TRIAL: Angiographic and infarction-related characteristics VARIABLE G-CSF (n. 29) Placebo (n. 27) P ECG involved leads, n (% ) Pts > 5 leads 14 (48) 13 (48) 0.79 Medium ST elevation (mm) 6 ± 4 5 ± Creatine kinase max U/L 4207 ± ± Troponin I peak 205 ± ± EF % 39.1 ± ± Killip class, n (%) Pts 3 7 (24) 3 (11) 0.29 IABP, n (%) 6 (21) 1 (4) 0.10 Onset of AMI to PCI, min 277 ± ± TIMI flow 0 pre PCI, n(%) 22 (76) 15 (56) 0.18 TIMI flow III post PCI, n(%) 24 (83) 25 (93) 0.47 PCI plus stent, n(%) 29 (100) 27 (100) 1.0 Drug eluting stent, n(%) 10 (35) 5 (19) 0.29 Multivessel disease, n(%) 15 (52) 8 (30) 0.15 PCI to G-CSF administration, min 553 ± 166 /
15 STEM-AMI SAFETY : Clinical Events over six months of follow-up EVENTS G-CSF (n 29) Placebo (n 27) p In hospital events, n Events from discharge to 6 months, n Death Reinfarction Ventricular arrhythmia AHF Stroke Death Reinfarction/ischemia Late stent thrombosis Target vessel restenosis Ventricular arrhythmia Heart failure Stroke Urgent revascularization MACE, n
16 STEM-AMI TRIAL: Effects of the G-CSF treatment on mobilization of SCs Data are expressed as cells/μl of peripheral blood. *=p<0.001
17 STEM-AMI TRIAL: Changes of LVEF by Echo and MRI ECHO MRI * Increase of LVEF from enrolment to baseline for G-CSF (p=0.006) and placebo (p=0.013); Increase of LVEF from enrolment to 6-months for G-CSF (p=0.016).
18 STEM-AMI TRIAL: Changes of LV volumes by MRI Panel A: Changes of normalized LVEDV Changes of normalized LVEDV from baseline to 6-months for placebo (p= ); Panel B: Changes of normalized LVESV # Changes of normalized LVESV from baseline to 6-months for placebo (p=0.016);
19 Scatterplots of the change of LVEDV from baseline to 6-months (Δ LVEDV) vs. time-toreperfusion in placebo (open square) and G- CSF (solid circles) groups. Solid lines represent the median of Δ LVEDV (9,3 ml) and time-toreperfusion (180 min.). * Upper right panel: patients with time-toreperfusion (T-to-R) > 180 min and Δ LVEDV > 9,3 ml. (p=0.0123).
20 STEM-AMI TRIAL: Infarct size: mean number of segments with LGE > 75% by MRI * Changes of mean number of segments with late gadolinium enhancement > 75% for G-CSF (p=0.04).
21 STEM-AMI TRIAL: Perfusion by SPECT: mean signal intensity (MSI) * Changes of MSI for G-CSF (p=0.005) and placebo (p=0.008).
22 STEM-AMI: Conclusions In patients with large anterior STEMI, EF 45% after reperfusion and a symptom-to-balloon time 2-12 hours, early administration (<12 hours) of G-CSF s.c. may attenuates 6-months unfavourable remodelling The analysis of the relationship between extent of remodelling and time-to-reperfusion has shown that the protective effect of G-CSF seems even more relevant when reperfusion time exceeds 3 hours About the possible mechanism involved in the G-CSF protective effect on LV remodelling, we observed a reduction in infarct size, suggesting that cells homing into the infarct zone may have played a role in reducing scar dimensions through the release of factors promoting infarct healing Large scale trials are now necessary to verify these hypothesis
Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes
Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Seung-Jae Joo and other KAMIR-NIH investigators Department of Cardiology, Jeju National
More informationARMYDA-RECAPTURE (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) trial
ARMYDA-RECAPTURE ( for Reduction of MYocardial Damage during Angioplasty) trial Prospective, multicenter, randomized, double blind trial investigating efficacy of atorvastatin reload in patients on chronic
More informationEffect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary PCI
Effect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary PCI Dr Sasha Koul, MD Dept of Cardiology, Lund University Hospital, Lund, Sweden
More informationSupplementary Material to Mayer et al. A comparative cohort study on personalised
Suppl. Table : Baseline characteristics of the patients. Characteristic Modified cohort Non-modified cohort P value (n=00) Age years 68. ±. 69.5 ±. 0. Female sex no. (%) 60 (0.0) 88 (.7) 0.0 Body Mass
More informationPeriprocedural Myocardial Infarction and Clinical Outcome In Bifurcation Lesion
Periprocedural Myocardial Infarction and Clinical Outcome In Bifurcation Lesion Hyeon-Cheol Gwon Cardiac and Vascular Center Samsung Medical Center Sungkyunkwan University School of Medicine Dr. Hyeon-Cheol
More informationAsian AMI Registry Session The 17 th Joint Meeting of Coronary Revascularization (JCR 2017) Busan, Korea Dec 8 th 2017
Asian AMI Registry Session The 17 th Joint Meeting of Coronary Revascularization (JCR 2017) Busan, Korea Dec 8 th 2017 Trends of acute myocardial infarction in Korea from the experience of Korea Acute
More informationCase Report Left Main Stenosis. Percutaneous Coronary Intervention (PCI) or Coronary Artery Bypass Graft Surgery (CABG)?
Cronicon OPEN ACCESS CARDIOLOGY Case Report Left Main Stenosis. Percutaneous Coronary Intervention (PCI) or Coronary Artery Bypass Graft Surgery (CABG)? Valentin Hristov* Department of Cardiology, Specialized
More informationLM stenting - Cypher
LM stenting - Cypher Left main stenting with BMS Since 1995 Issues in BMS era AMC Restenosis and TLR (%) 3 27 TLR P=.282 Restenosis P=.71 28 2 1 15 12 Ostium 5 4 Shaft Bifurcation Left main stenting with
More informationControversies in Cardiac Pharmacology
Controversies in Cardiac Pharmacology Thomas D. Conley, MD FACC FSCAI Disclosures I have no relevant relationships with commercial interests to disclose. 1 Doc, do I really need to take all these medicines?
More informationImaging congestive heart failure: role of coronary computed tomography angiography (CCTA)
Imaging congestive heart failure: role of coronary computed tomography angiography (CCTA) Gianluca Pontone, MD, PhD, FESC, FSCCT Director of MR Unit Deputy Director of Cardiovascul CT Unit Clinical Cardiology
More informationWhat oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor
76 year old female Prior Hypertension, Hyperlipidemia, Smoking On Hydrochlorothiazide, Atorvastatin New onset chest discomfort; 2 episodes in past 24 hours Heart rate 122/min; BP 170/92 mm Hg, Killip Class
More informationSafety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD
Safety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD Mun K. Hong, MD Associate Professor of Medicine Director, Cardiovascular Intervention and Research Weill Cornell
More informationGrowth-factor-induced mobilisation of stem cells after acute infarction: which growth factors and when?
Growth-factor-induced mobilisation of stem cells after acute infarction: which growth factors and when? Giulio Pompilio MD PhD DEPT. OF CARDIOVASCULAR SURGERY LABORATORY OF VASCULAR BIOLOGY AND REGENERATIVE
More informationISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions
Julinda Mehilli, MD Deutsches Herzzentrum Technische Universität Munich Germany ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions Background Left main
More informationRelationship between body mass index, coronary disease extension and clinical outcomes in patients with acute coronary syndrome
Relationship between body mass index, coronary disease extension and clinical outcomes in patients with acute coronary syndrome Helder Dores, Luís Bronze Carvalho, Ingrid Rosário, Sílvio Leal, Maria João
More informationSTEMI AND MULTIVESSEL CORONARY DISEASE
STEMI AND MULTIVESSEL CORONARY DISEASE ΤΣΙΑΦΟΥΤΗΣ Ν. ΙΩΑΝΝΗΣ ΕΠΕΜΒΑΤΙΚΟΣ ΚΑΡΔΙΟΛΟΓΟΣ Α ΚΑΡΔΙΟΛΟΓΙΚΗ ΝΟΣ ΕΡΥΘΡΟΥ ΣΤΑΥΡΟΥ IRA 30-50% of STEMI patients have additional stenoses other than the infarct related
More informationIschemic Postconditioning During Primary Percutaneous Coronary Intervention Mechanisms and Clinical Application Jian Liu, MD FACC FESC FSCAI Chief Phy
Ischemic Postconditioning During Primary Percutaneous Coronary Intervention Mechanisms and Clinical Application Jian Liu, MD FACC FESC FSCAI Chief Physician, Professor of Medicine Department of Cardiology,
More informationRecovering Hearts. Saving Lives.
Recovering Hearts. Saving Lives ṬM The Door to Unload (DTU) STEMI Safety & Feasibility Pilot Trial November 218 Recovering Hearts. Saving Lives. LEGAL DISCLAIMERS This presentation includes select slides
More informationSummary Protocol ISRCTN / NCT REVIVED-BCIS2 Summary protocol version 4, May 2015 Page 1 of 6
Summary Protocol REVIVED-BCIS2 Summary protocol version 4, May 2015 Page 1 of 6 Background: Epidemiology In 2002, it was estimated that approximately 900,000 individuals in the United Kingdom had a diagnosis
More informationEarly discharge in selected patients after an acute coronary syndrome can it be safe?
Early discharge in selected patients after an acute coronary syndrome can it be safe? Glória Abreu, Pedro Azevedo, Carina Arantes, Catarina Quina-Rodrigues, Sara Fonseca, Juliana Martins, Catarina Vieira,
More informationIschemic Heart Disease Interventional Treatment
Ischemic Heart Disease Interventional Treatment Cardiac Catheterization Laboratory Procedures (N = 89) is a regional and national referral center for percutaneous coronary intervention (PCI). A total of
More informationTicagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATO trial
compared with clopidogrel in patients with acute coronary syndromes the PLATO trial August 30, 2009 at 08.00 CET PLATO background In NSTE-ACS and STEMI, current guidelines recommend 12 months aspirin and
More informationSupplementary Table S1: Proportion of missing values presents in the original dataset
Supplementary Table S1: Proportion of missing values presents in the original dataset Variable Included (%) Missing (%) Age 89067 (100.0) 0 (0.0) Gender 89067 (100.0) 0 (0.0) Smoking status 80706 (90.6)
More information4. Which survey program does your facility use to get your program designated by the state?
STEMI SURVEY Please complete one survey for each TCD designation you have in your facility. There would be a maximum of three surveys completed if your facility was designated as a trauma, stroke and STEMI
More informationUnprotected LM intervention
Unprotected LM intervention Guideline for COMBAT Seung-Jung Park, MD, PhD Professor of Internal Medicine, Seoul, Korea Current Recommendation for unprotected LMCA Stenosis Class IIb C in ESC guideline
More informationAlex versus Xience Registry Preliminary report
Interventional Cardiology Network Alex versus Xience Preliminary report Mariusz Gąsior 1,2, Marek Gierlotka 1, Lech Poloński 1,2 1 3rd Department of Cardiology, Medical University of Silesia Centre tor
More informationSubsequent management and therapies
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation Subsequent management and therapies Marco Valgimigli, MD, PhD University of Ferrara ITALY
More informationInfluence of Location and Size of Myocardial Infarction on Post-infarction Remodelling
Influence of Location and Size of Myocardial Infarction on Post-infarction Remodelling Masci PG, MD ; Ganame J, MD ; Francone M, MD, PhD # ; Desmet W, MD ; Iacucci I, MD # ; Barison A, MD ; Carbone I,
More informationStem Cell Mobilization by Granulocyte Colony-Stimulating Factor for Myocardial Recovery After Acute Myocardial Infarction
Journal of the American College of Cardiology Vol. 51, No. 15, 2008 2008 by the American College of Cardiology Foundation ISSN 0735-1097/08/$34.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2007.11.073
More informationClopidogrel Date: 15 July 2008
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinicalTrials.gov
More informationAPPENDIX F: CASE REPORT FORM
APPENDIX F: CASE REPORT FORM Instruction: Complete this form to notify all ACS admissions at your centre to National Cardiovascular Disease Registry. Where check boxes are provided, check ( ) one or more
More informationIschemic Heart Disease Interventional Treatment
Ischemic Heart Disease Interventional Treatment Cardiac Catheterization Laboratory Procedures (N = 11,61) is a regional and national referral center for percutaneous coronary intervention (PCI). A total
More informationDisclosures. Speaker s bureau: Research grant: Advisory Board: Servier International, Bayer, Merck Serono, Novartis, Boehringer Ingelheim, Lupin
Disclosures Speaker s bureau: Research grant: Advisory Board: Servier International, Bayer, Merck Serono, Novartis, Boehringer Ingelheim, Lupin Servier International, Boehringer Ingelheim Servier International,
More informationVentricular tachycardia and ischemia. Martin Jan Schalij Department of Cardiology Leiden University Medical Center
Ventricular tachycardia and ischemia Martin Jan Schalij Department of Cardiology Leiden University Medical Center Disclosure: Research grants from: Boston Scientific Medtronic Biotronik Sudden Cardiac
More informationPatient characteristics Intervention Comparison Length of followup
ISCHAEMIA TESTING CHAPTER TESTING FOR MYCOCARDIAL ISCHAEMIA VERSUS NOT TESTING FOR MYOCARDIAL ISCHAEMIA Ref ID: 4154 Reference Wienbergen H, Kai GA, Schiele R et al. Actual clinical practice exercise ing
More informationRandomized Comparison of Prasugrel and Bivalirudin versus Clopidogrel and Heparin in Patients with ST-Segment Elevation Myocardial Infarction
Randomized Comparison of Prasugrel and Bivalirudin versus Clopidogrel and Heparin in Patients with ST-Segment Elevation Myocardial Infarction The Bavarian Reperfusion Alternatives Evaluation (BRAVE) 4
More informationCronicon CARDIOLOGY. N Laredj*, HM Ali Lahmar and L Hammou. Abstract
Cronicon OPEN ACCESS CARDIOLOGY Research Article Persistent Ischemia in Recovery Predicts Mortality after Myocardial Infarction in Patients Undergoing Dobutamine N Laredj*, HM Ali Lahmar and L Hammou Department
More informationAcute Coronary Syndrome. Sonny Achtchi, DO
Acute Coronary Syndrome Sonny Achtchi, DO Objectives Understand evidence based and practice based treatments for stabilization and initial management of ACS Become familiar with ACS risk stratification
More informationNova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines)
Cardiovascular Health Nova Scotia Guideline Update Nova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines) Authors: Dr. M. Love, Dr. I. Bata, K. Harrigan
More informationAbstract Background: Methods: Results: Conclusions:
Two-Year Clinical and Angiographic Outcomes of Overlapping Sirolimusversus Paclitaxel- Eluting Stents in the Treatment of Diffuse Long Coronary Lesions Kang-Yin Chen 1,2, Seung-Woon Rha 1, Yong-Jian Li
More informationShould All Patients Be Treated with Ace-inh /ARB after STEMI with Preserved LV Function?
Should All Patients Be Treated with Ace-inh /ARB after STEMI with Preserved LV Function? Avi Shimony, MD, FESC Cardiology Division Soroka University Medical Center Ben-Gurion University, Beer-Sheva Disclosure
More informationTarget vessel only revascularization versus complet revascularization in non culprit lesions in acute myocardial infarction treated by primary PCI
Target vessel only revascularization versus complet revascularization in non culprit lesions in acute myocardial infarction treated by primary PCI Gamal Abdelhady, Emad Mahmoud Department of interventional
More informationAdults With Diagnosed Diabetes
Adults With Diagnosed Diabetes 1990 No data available Less than 4% 4%-6% Above 6% Mokdad AH, et al. Diabetes Care. 2000;23(9):1278-1283. Adults With Diagnosed Diabetes 2000 4%-6% Above 6% Mokdad AH, et
More informationGALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS
GALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS Table of Contents List of authors pag 2 Supplemental figure I pag 3 Supplemental figure II pag 4 Supplemental
More informationManagement of stable CAD FFR guided therapy: the new gold standard
Management of stable CAD FFR guided therapy: the new gold standard Suleiman Kharabsheh, MD Director; CCU, Telemetry and CHU Associate professor of Cardiology, Alfaisal Univ. KFHI - KFSHRC Should patients
More informationClinical Seminar. Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective
Clinical Seminar Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical
More informationCHRONIC HEART FAILURE : WHAT ELSE COULD WE OFFER TO OUR PATIENTS? Cardiac Rehabilitation Society of Thailand
CHRONIC HEART FAILURE : WHAT ELSE COULD WE OFFER TO OUR PATIENTS? Cardiac Rehabilitation Society of Thailand ENHANCED EXTERNAL COUNTER PULSATION Piyanuj Ruckpanich, MD. Cardiac Rehabilitation Center Perfect
More informationThe ESC Registry on Chronic Ischemic Coronary Disease
EURObservational Research Programme The ESC Registry on Chronic Ischemic Coronary Disease Prof. Fausto J. Pinto, FESC, FACC, FASE, FSCAI Immediate Past-President, ESC University Hospital Sta Maria University
More informationDISCUSSION QUESTION - 1
CASE PRESENTATION 87 year old male No past history of diabetes, HTN, dyslipidemia or smoking Very active Medications: omeprazole for heart burn Admitted because of increasing retrosternal chest pressure
More informationWhat is the Optimal Triple Anti-platelet Therapy Duration in Patients with Acute Myocardial Infarction Undergoing Drug-eluting Stents Implantation?
What is the Optimal Triple Anti-platelet Therapy Duration in Patients with Acute Myocardial Infarction Undergoing Drug-eluting Stents Implantation? Keun-Ho Park, Myung Ho Jeong, Min Goo Lee, Jum Suk Ko,
More informationSTEMI Presentation and Case Discussion. Case #1
STEMI Presentation and Case Discussion Scott M Lilly MD PhD, Interventional Cardiology The Ohio State University Contemporary Multidisciplinary Cardiovascular Conference Orlando, Florida September 17 th,
More informationCan point of care cardiac biomarker testing guide cardiac safety during oncology trials?
Can point of care cardiac biomarker testing guide cardiac safety during oncology trials? Daniel J Lenihan, MD Professor, Division of Cardiovascular Medicine Director, Clinical Research Vanderbilt University
More informationSTEMI Stents What next? Arshad Khan - HNE Clinical Research Fellow. Supervisors: Prof Boyle and Attia.
STEMI Stents What next? Arshad Khan - HNE Clinical Research Fellow. Supervisors: Prof Boyle and Attia. PART 1 Systems of care for STEMI. STEMI Management Coronary angiogram +/- stenting. Prehospital thrombolysis
More informationStable Angina: Indication for revascularization and best medical therapy
Stable Angina: Indication for revascularization and best medical therapy Cardiology Basics and Updated Guideline 2018 Chang-Hwan Yoon, MD/PhD Cardiovascular Center, Department of Internal Medicine Bundang
More informationCoronary microvascular dysfunction after elective percutaneous coronary intervention: correlation with exercise stress test results
Department of Cardiovascular Medicine Università Cattolica del Sacro Cuore Rome, Italy Coronary microvascular dysfunction after elective percutaneous coronary intervention: correlation with exercise stress
More informationLack of Effect of Beta-blocker Therapy in Patients with ST-elevation Acute Myocardial Infarction in PCI Era
Lack of Effect of Beta-blocker Therapy in Patients with ST-elevation Acute Myocardial Infarction in PCI Era B. Bao 1, N. Ozasa 1, T. Morimoto 2, Y. Furukawa 3, M. Shirotani 4, H. Ogawa 5, C. Tei 6, H.
More informationIs it safe to discharge patients 24 hours after uncomplicated successful primary percutaneous coronary intervention
Is it safe to discharge patients 24 hours after uncomplicated successful primary percutaneous coronary intervention DA Jones, J Howard, S Gallagher, KS Rathod, A Jain, S Mohiddin, C Knight, A Mathur, EJ
More informationClinical Considerations for CTO Revascularization
Clinical Considerations for CTO Revascularization Whom to treat, Who derives benefit and What can we achieve? David E. Kandzari, MD, FACC, FSCAI Chief Medical Officer Cordis Cardiology Johnson & Johnson
More informationΔιάρκεια διπλής αντιαιμοπεταλιακής αγωγής. Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά
Διάρκεια διπλής αντιαιμοπεταλιακής αγωγής Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά International ACS guidelines: Recommendations on duration of dual
More informationM/39 CC D. => peak CKMB (12 hr later) ng/ml T.chol/TG/HDL/LDL 180/150/48/102 mg/dl #
Acute Coronary Syndrome - Case Review - Young-Guk Ko, MD Yonsei Cardiovascular Center Yonsei University College of Medicine Case 1 M/39 #4306212 CC D : Severe squeezing chest pain : 4 hours, aggravated
More informationAcute Myocarditis Mimicking ST-segment Elevation Myocardial Infarction: Relation Between ECG Changes And Myocardial Damage As Assessed By CMR
Acute Myocarditis Mimicking ST-segment Elevation Myocardial Infarction: Relation Between ECG Changes And Myocardial Damage As Assessed By CMR G. Nucifora 1, A. Di Chiara 2, D. Miani 1, G. Piccoli 3, M.
More informationA case of post myocardial infarction ventricular septal rupture CHRISTOFOROS KOBOROZOS, MD
A case of post myocardial infarction ventricular septal rupture CHRISTOFOROS KOBOROZOS, MD NAVAL HOSPITAL OF ATHENS case presentation Female, 81yo Hx: diabetes mellitus, hypertension, chronic anaemia presented
More informationTCTAP Upendra Kaul MD,DM,FACC,FSCAI,FAMS,FCSI
Indian TUXEDO Trial In Medically Treated Diabetics Upendra Kaul MD,DM,FACC,FSCAI,FAMS,FCSI Executive Director and Dean Escorts Heart Institute & Medical Research Center and Fortis Hospitals, New Delhi
More informationCardiovascular Health Nova Scotia Update to Antiplatelet Sections of the Nova Scotia Guidelines for Acute Coronary Syndromes, 2008.
Cardiovascular Health Nova Scotia Update to Antiplatelet Sections of the Nova Scotia Guidelines for Acute Coronary Syndromes, 2008. ST Elevation Myocardial Infarction (STEMI)-Acute Coronary Syndrome Guidelines:
More informationImpact of Thromboaspiration during Primary PCI on infarcted segmental myocardial function: a Tissue Doppler imaging evaluation. EXPIRA Trial substudy.
Impact of Thromboaspiration during Primary PCI on infarcted segmental myocardial function: a Tissue Doppler imaging evaluation. EXPIRA Trial substudy. GENNARO SARDELLA, MD, FACC,FESC; MASSIMO MANCONE,
More informationThe Case for Multivessel Revascularization in Shock
The Case for Multivessel Revascularization in Shock Emmanouil S. Brilakis, MD, PhD Minneapolis Heart Institute 9.37 9.49 am Disclosures Consulting/speaker honoraria: Abbott Vascular, American Heart Association
More informationStem Cells. Keith Channon. Department of Cardiovascular Medicine University of Oxford John Radcliffe Hospital, Oxford
Stem Cells Keith Channon Department of Cardiovascular Medicine University of Oxford John Radcliffe Hospital, Oxford Adult Stem Cells Unique cells that are capable of self-renewal Have the ability to differentiate
More informationManagement of Acute Myocardial Infarction
Management of Acute Myocardial Infarction Prof. Hossam Kandil Professor of Cardiology Cairo University ST Elevation Acute Myocardial Infarction Aims Of Management Emergency care (Pre-hospital) Early care
More informationCORONARY CHRONIC TOTAL OCCLUSIONS IN THE SETTING OF ACUTE MYOCARDIAL INFARCTION
CORONARY CHRONIC TOTAL OCCLUSIONS IN THE SETTING OF ACUTE MYOCARDIAL INFARCTION *Bimmer Claessen, Loes Hoebers, José Henriques Department of Cardiology, Academic Medical Center, University of Amsterdam,
More informationFacilitated Percutaneous Coronary Intervention in Acute Myocardial Infarction. Is it beneficial to patients?
Facilitated Percutaneous Coronary Intervention in Acute Myocardial Infarction Is it beneficial to patients? Seung-Jea Tahk, MD. PhD. Suwon, Korea Facilitated PCI.. background Degree of coronary flow at
More informationALTERNATIVE APPROACH FOR END-STAGED ISCHEMIC CARDIOMYOPATHY WITH LV ANEURYSM COMBINING SURGICAL AND CELL THERAPY THESSALONIKI, 2018
ALTERNATIVE APPROACH FOR END-STAGED ISCHEMIC CARDIOMYOPATHY WITH LV ANEURYSM COMBINING SURGICAL AND CELL THERAPY THESSALONIKI, 2018 Kostas Katsavrias Sotirios N. Prapas A Cardiac Surgery Dpt Henry Dunant
More informationSHOULD BETA BLOCKERS BE USED ROUTINELY IN POST MI PATIENTS WITH PRESERVED LV FUNCTION?
SHOULD BETA BLOCKERS BE USED ROUTINELY IN POST MI PATIENTS WITH PRESERVED LV FUNCTION? Doron Zahger, MD Department of Cardiology, Soroka University Medical Center, Faculty of Health Sciences, Ben Gurion
More informationCardiology. Self Learning Package. Module 5: Pharmacology: Treatment of Acute Coronary. Prevention
Cardiology Self Learning Package Module 5: Pharmacology: Treatment of Acute Coronary Syndromes, Module 5: Pharmacology: Hyperlipidaemia, Treatment of Acute Coronary Hypertension, Symdrome, Hyperlipidaemia,
More informationPrognostic Value of Intramyocardial Hemorrhage Detected by Cardiac Magnetic Resonance Imaging in Acute Reperfused ST-Elevation Myocardial Infarction
Prognostic Value of Intramyocardial Hemorrhage Detected by Cardiac Magnetic Resonance Imaging in Acute Reperfused ST-Elevation Myocardial Infarction Holger Thiele, MD; Konrad Kubusch, BSc; Steffen Desch,
More informationApproach to Multi Vessel disease with STEMI
Approach to Multi Vessel disease with STEMI MANAGEMENT OF ST-ELEVATION MYOCARDIAL INFARCTION Dr. Thomas Alexander, M.D; D.M; F.A.C.C. Senior Consultant and Interventional Cardiologist Kovai Medical Centre
More informationTicagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATelet Inhibition and patient Outcomes trial
compared with clopidogrel in patients with acute coronary syndromes the PLATelet Inhibition and patient Outcomes trial Outcomes in patients with and planned PCI Ph.Gabriel Steg*, Stefan James, Robert A
More informationEXAMINATION trial. Manel Sabaté Hospital Clínic, Barcelona (On behalf of the Examination Investigators)
Manel Sabaté Hospital Clínic, Barcelona (On behalf of the Examination Investigators) Disclosures Investigator Initiated Trial: NCT00828087. Unrestricted grant from Abbott to the Spanish Heart Foundation.
More informationHow to approach non-infarct related artery disease in patients with STEMI in a limited resource setting
How to approach non-infarct related artery disease in patients with STEMI in a limited resource setting Ahmed A A Suliman, MBBS, FACP, FESC Associate Professor, University of Khartoum Interventional Cardiologist,
More informationCoronary Catheterization and Percutaneous Coronary Intervention in China 10-Year Results From the China PEACE-Retrospective CathPCI Study
Coronary Catheterization and Percutaneous Coronary Intervention in China 10-Year Results From the China PEACE-Retrospective CathPCI Study Xin Zheng, MD, PhD; Jeptha P. Curtis, MD; Shuang Hu, PhD; YongfeiWang,
More informationFinal Kissing Ballooning Returns? The analysis of COBIS II registry
Final Kissing Ballooning Returns? The analysis of COBIS II registry Hyeon- Cheol Gwon Heart Vascular & Stroke Ins?tute, Samsung Medical Center Sungkyunkwan University School of Medicine Final Kissing Ballooning
More information8th Emirates Cardiac Society Congress in collaboration with ACC Middle East Conference Dubai: October Acute Coronary Syndromes
8th Emirates Cardiac Society Congress in collaboration with ACC Middle East Conference 2017 OSPEDALE Dubai: 19-21 October 2017 Acute Coronary Syndromes Antonio Colombo Centro Cuore Columbus and S. Raffaele
More informationANGIOPLASY SUMMIT 2007 TCT ASIA PACIFIC. Seoul, Korea: April The problem is exaggerated: Data from Real World Registries
ANGIOPLASY SUMMIT 007 TCT ASIA PACIFIC Seoul, Korea: 5-7 7 April 007 15 min Plenary Session: State-of of-the-art Lectures The problem is exaggerated: Data from Real World Registries Antonio Colombo Centro
More informationStatistical analysis plan
Statistical analysis plan Prepared and approved for the BIOMArCS 2 glucose trial by Prof. Dr. Eric Boersma Dr. Victor Umans Dr. Jan Hein Cornel Maarten de Mulder Statistical analysis plan - BIOMArCS 2
More informationImaging and heart failure
Imaging and heart failure Jeroen J Bax Dept of Cardiology Leiden Univ Medical Center The Netherlands Davos, feb 2013 Research grants: Medtronic, Biotronik, Boston, St Jude, BMS imaging, GE Healthcare,
More informationCardiology Department Coimbra Hospital and Medical School Portugal
Quantitative troponin elevation provide incremental prognostic value beyond comprehensive risk stratification in patients with acute coronary syndromes. Rui Baptista, Elisabete Jorge, Hélia Martins, Fátima
More informationQuale terapia antiaggregante nello STEMI? Prasugrel vs ticagrelor
Quale terapia antiaggregante nello STEMI? Prasugrel vs ticagrelor Leonardo Bolognese Cardiovascular Department, Arezzo, Italy Platelet Reactivity in Patients with STEMI Undergoing Primary PCI Campo G et
More informationChronic Total Occlusion: A case for coronary artery bypass grafting
Chronic Total Occlusion: A case for coronary artery bypass grafting Prof. Alfredo R Galassi MD, FESC, FACC, FSCAI Director of Cardiac Catheterization and Interventional Cardiology Unit Department of Medical
More informationStem Cell Therapy in Acute Myocardial Infarction: hype or reality?
Stem Cell Therapy in Acute Myocardial Infarction: hype or reality? Stefan Janssens, MD, PhD Department of Cardiology Gasthuisberg University Hospital Leuven, Belgium No disclosures Brussels, 8-12-27 Cardiac
More informationQuality Payment Program: Cardiology Specialty Measure Set
Quality Payment Program: Cardiology Specialty Set Title Number CMS Reporting Method(s) Heart Failure (HF): Angiotensin- Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST How to manage antiplatelet treatment in patients with diabetes in acute coronary syndrome Lars Wallentin Professor of Cardiology, Chief Researcher Cardiovascular Science
More informationClinical Investigations
Clinical Investigations Deeply Reinverted T Wave at 14 Days After the Onset of First Anterior Acute Myocardial Infarction Predicts Improved Left Ventricular Function at 6 Months Address for correspondence:
More informationProgram Metrics. New Unique ID. Old Unique ID. Metric Set Metric Name Description. Old Metric Name
Program Metrics The list below includes the metrics that will be calculated by the PINNACLE Registry for the outpatient office setting. These include metrics for, Atrial Fibrillation, Hypertension and.
More informationJournal of the American College of Cardiology Vol. 48, No. 8, by the American College of Cardiology Foundation ISSN /06/$32.
Journal of the American College of Cardiology Vol. 48, No. 8, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2006.07.044
More information(ClinicalTrials.gov ID: NCT ) Title: The Italian Elderly ACS Study Author: Stefano Savonitto. Date: 29 August 2011 Meeting: ESC congress, Paris
Early aggressive versus initially conservative strategy in elderly patients with non-st- elevation acute coronary syndrome: the Italian randomised trial (ClinicalTrials.gov ID: NCT00510185) Stefano Savonitto,
More informationLessons learned From The National PCI Registry
Lessons learned From The National PCI Registry w a v e On Behalf of The Publication Committee of the National PCI Registry Objectives & Anticipated Achievements To determine the epidemiology of patients
More informationBalancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients
SYP.CLO-A.16.07.01 Balancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients dr. Hariadi Hariawan, Sp.PD, Sp.JP (K) TOPICS Efficacy Safety Consideration from Currently Available Antiplatelet Agents
More informationPharmaco-Invasive Approach for STEMI
Pharmaco-Invasive Approach for STEMI Michael C. Kontos, MD Medical Director, Coronary Intensive Care Unit Director, Chest Pain Evaluation Center Associate Professor Departments of Internal Medicine (Cardiology),
More informationPre Hospital and Initial Management of Acute Coronary Syndrome
Pre Hospital and Initial Management of Acute Coronary Syndrome Dr. Muhammad Fadil, SpJP 3rd SymCARD 2013 Classification of ACS ESC Guidelines for the management of Acute Coronary Syndrome in patients without
More informationIs bypass surgery needed for elderly patients with LMT disease? From the surgical point of view
CCT 2003 (Kobe) Is bypass surgery needed for elderly patients with LMT disease? From the surgical point of view Hitoshi Yaku, MD, PhD Department of Cardiovascular Surgery Kyoto Prefectural University of
More informationIntervention: How and to which extent is technology helping us?
Cardiological Society of India Congress 12th February 2016 Chennai, India Intervention: How and to which extent is technology helping us? SIMONE BISCAGLIA MD CARDIOVASCULAR INSTITUTE, FERRARA, ITALY Introduction
More information